<DOC>
	<DOCNO>NCT00174746</DOCNO>
	<brief_summary>To investigate efficacy safety ciclesonide inhale lung range dose new dry powder inhaler compare ciclesonide inhaled lung use meter dose inhaler</brief_summary>
	<brief_title>Dose Response Study Inhaled Ciclesonide ( Glucocorticosteroid ) Patients With Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>Males females 12 year old ; History persistent bronchial asthma least 6 month ; Documented use inhale steroid least 1 month screening ; At screening , FEV1 40 % predict normal randomization , FEV1 40 80 % predict normal ; Reversibility FEV1 least 12 % 200 ml postbronchodilator ; Be able use oral inhaler ; Nonsmokers History lifethreatening asthma ; pulmonary disease ; URI within 4 week screen ; Use systemic steroid within 1 month screen 3 time previous 6 month ; betaadrenergic block agent use ; More 2 inpatient hospitalization ER visit due asthma exacerbation prior year screening ; Pregnant breastfeeding female ; Females childbearing potential use adequate mean birth control ; Clinically relevant cardiovascular , hepatic , neurologic , endocrine , major systemic disease ; Abnormal clinical laboratory parameter would limit participation study interfere interpretation study result ; History drug alcohol abuse ; Treatment investigational product within 30 day prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Glucocorticosteroid ; Dose response ; Bronchospasm</keyword>
</DOC>